Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Promotions bring execs to the top spots at ostomy and wound-care specialist Coloplast AS, imaging solutions and ortho surgical care company EOS Imaging, and ophthalmics AI firm Notal Vision. Those and more recent medtech personnel moves.
This week, a new corporate development senior VP arrives at clinical and research diagnostics firm Abcam, a VP opts out of business development post at Danaher to strategize for Agilent Tech, and a supply chain exec departs J&J.
New chairs of InvitroCue's medical advisory board, Predictive Technology's clinical advisory board and B. Braun Melsungen's management board.
Medtronic co-founder and cardiac rhythm management pioneer, Earl Bakken, passed away Oct. 21 at his home in Kiholo, Hawaii at age 94.
In this week's roundup, a sudden retirement from the CEO of ConvaTec. And Medovex, which makes a minimally device to address chronic back pain, replaced its CEO. More executive comings and goings from around the industry.
Christopher Barry, who has run Medtronic's Surgical Innovations business since 2015, will become the new CEO of NuVasive Inc. on Nov. 5. See what current NuVasive CEO Gregory Lucier, who will stay with the spine-surgery company as the chairman of its board of directors, said about Barry's appointment here.
About three years after becoming CEO of NuVasive, Gregory Lucier is ceding the role to Barry, who has led Medtronic's Surgical Innovations business, effective Nov. 5. Lucier will continue to serve as chairman of the board for the San Diego-based minimally-invasive spine surgery technology company.
Recent moves up the ladder: new COOs at Beckton Dickinson and Abbott, a chief technology officer at LuxCath, and a chief growth officer at Varian Medical. In addition, the chairman of BTG announced his decision to depart at the end of the year.
The company's device business chief is expanding his portfolio as Abbott's new president and chief operating officer, leading to some speculation that he is being positioned to be the next CEO.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.